Sarepta Therapeutics, Inc. Stock price

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
124 USD +0.75% Intraday chart for Sarepta Therapeutics, Inc. +1.97% +28.56%
Sales 2024 * 1.82B Sales 2025 * 2.95B Capitalization 11.64B
Net income 2024 * 222M Net income 2025 * 1.08B EV / Sales 2024 * 5.69 x
Net cash position 2024 * 1.27B Net cash position 2025 * 2.39B EV / Sales 2025 * 3.14 x
P/E ratio 2024 *
49.1 x
P/E ratio 2025 *
11 x
Employees 1,314
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.21%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating MT
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37 MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
More news
1 day+0.75%
1 week+1.97%
Current month-3.07%
1 month-7.90%
3 months+31.98%
6 months+5.01%
Current year+28.56%
More quotes
1 week
120.58
Extreme 120.58
125.41
1 month
119.65
Extreme 119.645
142.60
Current year
91.34
Extreme 91.3439
143.00
1 year
55.25
Extreme 55.25
159.89
3 years
55.25
Extreme 55.25
159.89
5 years
55.25
Extreme 55.25
181.83
10 years
8.00
Extreme 8
181.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 17-06-25
Director of Finance/CFO 48 14-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 61 17-06-25
Chairman 71 09-03-30
Director/Board Member 65 15-06-01
More insiders
Date Price Change Volume
24-03-18 124 +0.75% 523,125
24-03-15 123 -0.57% 1,245,799
24-03-14 123.8 +1.48% 644,210
24-03-13 122 -0.03% 684,537
24-03-12 122 +0.35% 732,440

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It develops therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
124 USD
Average target price
164.3 USD
Spread / Average Target
+32.55%
Consensus
  1. Stock
  2. Equities
  3. Stock Sarepta Therapeutics, Inc. - Nasdaq